Pharmacists are optimally positioned and play a key role in reducing warfarin and dabigatran related adverse events and potential hospital admissions by ensuring patients have a good understanding of their therapy, including, but not limited to:

    • The indication for their OAC treatment
    • The duration of treatment eg lifelong or a set period
    • The potential adverse effects and the signs and symptoms of these
    • The potential medication and herbal interactions
    • Any other external factors that will affect their therapy eg non-adherence
    • The role of regular INR tests while on warfarin
    • The significance of a patient’s kidney function when on dabigatran
Pharmacists are to complete and pass this accreditation before service provision can commence.